First-generation EGFR-TKIs (Gefitinib and Erlotinib) and second-generation EGFR-TKI (Afatinib) significantly improved the prognosis of advanced NSCLC patients compared to platinum-based chemotherapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.